Description:
C10539: Use of Biomarker for Colon Cancer Diagnosis
Value Proposition:
ADVANTAGES
• Colon cancer biomarker is directly included in panels of biomarkers for use in needle biopsies of colon tissue for early detection and diagnosis.
• Colon cancer is the second largest mortality after cardiovascular disease. 90% of colorectal cancers can be successfully treated with early detection and diagnosis.
• Tissue-based diagnostics offer higher specificity and sensitivity over the blood-based biomarker assays.
• Tissue-based diagnostics provide a low error rate, high acceptance and broad range of applications in modern healthcare.
• The market for colon cancer diagnostics is expected to grow 11% annually between 2007-2012.
Technical Details:
BACKGROUND
Angiogenesis, the growth of new blood vessels from existing ones, is essentially required during embryonic development, formation of vasculature, wound healing and rebuilding of the uterus lining. When angiogenesis becomes unregulated for reasons that are not fully appreciated, growth pathologies such as diabetic vasculopathies, tumor growth, arthritis and other inflammatory diseases result. Specifically in cancer, however, the detection of growth pathology has not yet been realized in the clinic, such that diagnosis comes too late for early treatment or surgical intervention. Early detection of cancer is integral for improved survival outcomes.
TECHNOLOGY
This technology offers diagnostic application as a biomarker for colon cancer. In human colon cancer endothelial cells, the mRNA transcript of an isoform of an enzyme involved in the angiogenic signaling pathway was markedly over expressed 4.5-fold in human tumor endothelial cells compared to normal human endothelial cells, thus enabling efficient and early detection of unregulated angiogenesis in human colon cancer.
Looking for Partners:
This invention has application as a biomarker that involves the use of elevated levels of mRNA as a biomarker for colon cancer. In addition, tissue-based biomarkers have application to provide integral data for drug discovery, pharmacodynamics studies and for selection and monitoring of clinical therapy.
Publications/Associated Cases:
Antonina K., Rajesh, M., Zang, D., Pilli, R., & Chatterjee, S. (2009). VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconj J, doi: 10.1007/s10719-008-9206-9
